6.09
+0.86(+16.44%)
Currency In USD
| Previous Close | 5.23 |
| Open | 5.25 |
| Day High | 6.3 |
| Day Low | 5.19 |
| 52-Week High | 12.36 |
| 52-Week Low | 3.79 |
| Volume | 91.51M |
| Average Volume | 26.53M |
| Market Cap | 2.62B |
| PE | -3.56 |
| EPS | -1.71 |
| Moving Average 50 Days | 5.1 |
| Moving Average 200 Days | 5.83 |
| Change | 0.86 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $194.57 as of October 08, 2025 at a share price of $6.09. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $558.72 as of October 08, 2025 at a share price of $6.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BSTSalt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically imp
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
GlobeNewswire Inc.
Jun 06, 2025 2:00 PM GMT
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks